Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Innocore Sales & Marketing Inc.
WARNING LETTER
•Innocore Sales & Marketing Inc.•April 25, 2025

Innocore Sales & Marketing Inc. – FDA Warning Letter, Apr 25, 2025

Record Details

The FDA issued a Warning Letter to The Tranzonic Companies/Innocore Sales & Marketing Inc. following an inspection from April 22 to 25, 2025. The letter outlined significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, resulting in adulterated drug products under federal law. Key issues included the company"s failure to conduct adequate laboratory testing for finished drug products, specifically regarding the identity and strength of active ingredients and the absence of objectionable microorganisms prior to release. This meant a lack of scientific evidence that products met specifications.

Additionally, the company failed to perform sufficient identity testing on incoming drug components, particularly those at high risk for contamination with hazardous substances like diethylene glycol (DEG) and ethylene glycol (EG), which can be lethal.

Required actions by the FDA include a comprehensive, independent assessment of laboratory practices and a detailed remediation plan. The company must establish clear chemical and microbiological specifications for all products and provide an action plan for testing retain samples of distributed batches still within expiry, initiating recalls if quality issues are found. Immediate testing of high-risk components or finished products for DEG/EG contamination is required within 30 days. A thorough risk assessment for products potentially containing DEG/EG-prone ingredients is also mandated, alongside actions to secure supply chains, ensure component safety, and detail plans for robust component testing, including specific identity tests for every incoming lot.

Company
Innocore Sales & Marketing Inc.
Inspection date
April 25, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · dea81987-87a2-41e8-84c3-9be0477298f0

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 210FD&C Act 501(a)(2)(B)21 CFR 211.165(a)21 CFR 211.84(d)(1)21 CFR 211.2221 CFR 211.188FD&C Act 801(a)(3)21 CFR 21121 CFR 211.165(b)

Full citation text and observation details available on the Dashboard.

Other documents for Innocore Sales & Marketing Inc.
  • 483 - 2025-04-25April 25, 2025
  • 483 - 2019-06-06June 6, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Innocore Sales & Marketing Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.